SSSajeevan Sujanthan

Sajeevan Sujanthan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sajeevan Sujanthan has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Major Adverse Cognitive Events (MACE-Cog): A New “MACE” Framework for Cognitive Outcomes in Cardiovascular Diseases and Stroke

    by Aravind Ganesh, Sajeevan Sujanthan, Ryan T. Muir, Raed A. Joundi, Michael D. Hill, Terence J. Quinn, Bijoy Menon, Tolulope Sajobi, Jennifer S. Rabin, Katie N. Dainty, et al.

    Cardiovascular diseases, particularly stroke, are leading causes of dementia. Several common cardiac interventions such as coronary artery bypass grafting and transcatheter aortic valve implantation are also associated with cognitive decline. However, cognitive outcomes continue to be poorly collected in clinical trials of cardiovascular diseases. In this article, we review the limitations of current approaches to cognitive assessment in cardiovascular disease studies. When assessed, there is wide variation in cognitive tasks used, and tasks have limited population-specific validation, are subject to floor and ceiling effects, and may suffer from sociocultural and linguistic biases. Many tasks are not available in multilingual formats and often rely on face-to-face testing with trained coordinators. All conventional cognitive outcomes in cardiovascular trials are associated with substantial incompletion, especially among older and more impaired individuals, the very people most important to capture. This nonrandom missingness generates survivor and attrition biases, an unacceptable situation for any trial outcome. Last, the meaning of measured cognitive outcomes is often unclear for patients, caregivers, clinicians, and regulators. To help address these limitations, we propose a new framework, major adverse cognitive events (MACE-Cog), to better capture cognitive outcomes in stroke and other cardiovascular populations. As an inclusive construct reflecting the multidimensional nature of cognitive decline, major adverse cognitive events do not rely solely on performance on cognitive testing but also consider inability to complete cognitive testing due to cognitive-behavioral factors, reported symptoms of cognitive decline, impairment in activities of daily living as a result of cognitive impairment, new clinical diagnoses of dementia, and care home admission. We hope that the proposed composite outcome and multiple use cases presented spark progress in cardiovascular research toward more inclusive approaches to the study of cognitive outcomes that move beyond the confines of cognitive tests alone.


  • Open Access

    SMPD3 suppresses oligodendroglioma growth via dual autocrine-paracrine roles

    by Fermisk Saleh, Anjali Balakrishnan, Lata Adnani, Shiekh Tanveer Ahmad, Vorapin Chinchalongporn, Ahmed El-Sehemy, Thomas Olender, Myra J. Chen, Aditya Kshirsagar, Andrew Kennedy, et al.

    Oligodendrogliomas (ODGs) are slow-growing tumors with poorly defined biology. Here, we identify SMPD3, encoding neutral sphingomyelinase 2 (nSMase2), as a negative regulator of ODG progression via extracellular vesicle (EV) biogenesis and autocrine-paracrine signaling. High SMPD3 expression correlates with longer survival in ODG and low-grade glioma patients. SMPD3 knockdown in patient-derived BT54 and BT88 cells increases proliferation, enhances BT88 invasion in cerebral organoids, and accelerates BT88-tumor growth in mouse xenografts and chick CAM assays. Patient tumors display abnormal non-neoplastic glial proliferation and a ribosome-rich transcriptional signature in tumor-associated oligodendrocytes. Concordantly, ODG-derived EVs, enriched in ribosomal proteins, suppress astrocyte proliferation. Pharmacological inhibition of nSMase2 (GW4869) or ribosome biogenesis (Rbin1, diazaborine) increases ODG cell proliferation while reducing protein synthesis. Blocking EV synthesis amplifies ribosome inhibition effects, whereas exogenous EVs attenuate them. Thus, SMPD3-mediated EV signaling and ribosomal stress converge to regulate ODG proliferation, establishing SMPD3 as a key regulator and potential therapeutic target.


  • Open Access

    Cognitive Outcomes in Randomized Controlled Trials of Coronary Artery Bypass Graft Surgery From 2005 to 2025: A Systematic Review

    by Shantanu Srivatsa, Sajeevan Sujanthan, Sydni Paleczny, David A. Ripsman, Stephanie Niño de Rivera, Arnaldo Dimagli, Foad Taghdiri, Pai‐Shan Cheng, Wendy Lou, Michael E. Farkouh, et al.

    Background: Cognitive decline after coronary artery bypass graft (CABG) is common and affects morbidity, mortality, and quality of life. We systematically reviewed randomized CABG trial control arms to characterize cognitive assessments, testing frequency, attrition, and ability to detect perioperative change. Methods: We searched MEDLINE, Embase, Cochrane Library, and PsycINFO for randomized controlled trials of CABG surgery that included at least one arm of patients solely undergoing CABG and that reported at least one objective cognitive assessment, from January 2005 to February 2025. Trials with mixed cardiac surgery or only subjective measures were excluded. We summarized task frequency, cognitive domains, and attrition. For tasks assessed preoperatively and postoperatively in ≥3 trials, we reported control group means and SDs. Risk of bias was assessed using the Cochrane Risk of Bias tool among 6 bias domains. This study was supported by NIH–R01NS123639. Results: Of 3494 screened studies, 2284 were CABG trials, and only 71 (3.1%) reported cognitive evaluation. These involved 15 925 patients (79% men; mean age, 64.2 years; median follow‐up, 90 days) and used 145 unique cognitive tasks, with the Trail Making Test Part B (40 of 71; 56.3%) and Part A (38 of 71; 53.5%) being the most frequently administered. Among 7 tasks with sufficient data, none detected preoperative to postoperative changes. Attrition rates averaged 18.9%, with a broad range of 0 to 62%. Conclusions: Cognitive assessment is uncommon in CABG trials, and commonly used tests rarely detect change. Heterogeneity precluded meta‐analysis, and high attrition raises concerns about selection and survivorship bias. To evaluate cognitive impact after CABG, trials need standardized, sensitive assessment strategies resilient to attrition and feasible for broad deployment.


  • Faster Thrombolysis Is Associated With Improved Cognitive Outcomes in Patients With Acute Ischemic Stroke Treated With Alteplase and Tenecteplase: A Substudy of the AcT Trial

    by Sajeevan Sujanthan, Gayathiri Rajkumar, Katie N. Dainty, Morgan Barense, Krista L. Lanctot, Adrian M. Owen, Nishita Singh, Brian H. Buck, Houman Khosravani, Shelagh B. Coutts, et al.

    BACKGROUND: Cognitive impairment after stroke is linked with poorer functional outcomes. Faster thrombolytic improves recanalization, 3-month functional recovery, and in-hospital survival. We examined whether faster treatment times from door-to-needle and symptom onset-to-needle (OTN) impacted cognition. METHODS: This study is a prespecified secondary observational cohort analysis of the AcT randomized clinical trial (Alteplase Compared to Tenecteplase; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03889249) data. Eligible participants were English-speaking individuals who independently completed the trial’s primary outcome and were recruited from 18 stroke centers within Canada. Prospective cognitive outcomes were collected at 90 to 180 days using a Telephone Montreal Cognitive Assessment (T-MoCA range, 0–22; <17 impairment). The primary aim was to assess cognitive performance and its relationship with treatment times (door-to-needle and OTN) at 90 to 180 days. Linear and logistic regression analyses were used to evaluate the relationship, adjusting for treatment allocation, age, sex, baseline National Institutes of Health Stroke Scale, education, ethnicity, and occlusion location. RESULTS: Three hundred ninety-nine (50%) of 791 eligible subjects completed the T-MoCA. The mean age was 66±13 years, 38.8% were female, and the mean T-MoCA score was 16±4. Shorter OTN times (but not door-to-needle) were associated with higher T-MoCA scores on linear regression (β, −0.009 [95% CI, −0.016 to −0.002]) and with increased odds of T-MoCA impairment for every 1-minute increase on logistic regression (odds ratio, 1.005 [95% CI, 1.001–1.009]). There was no difference between the alteplase and tenecteplase subgroups in the relationship between treatment times and cognition. Each 15-minute reduction in OTN was associated with a 7.3% reduction in the probability of impairment (score <17) on the T-MoCA. CONCLUSIONS: Faster OTN time, with either alteplase or tenecteplase, was associated with higher T-MoCA scores and reduced the likelihood of impairment at 90 days. Faster thrombolytic treatment may reduce cognitive burden after stroke.


  • Open Access

    Feasibility of telephone and computerized cognitive testing as a secondary outcome in an acute stroke clinical trial: A mixed methods sub-study of the AcT Trial

    by Sajeevan Sujanthan, Pugaliya Puveendrakumaran, Katie N Dainty, Morgan Barense, Krista L Lanctot, Adrian M Owen, Nishita Singh, Brian H Buck, Houman Khosravani, Shelagh B Coutts, et al.

    Introduction: Post-stroke cognitive impairment is associated with impaired quality of life. Remote testing provides a potential avenue to measure cognitive outcomes efficiently. Patients and Methods: Prospective cognitive outcomes were collected at 90–180 days using both telephone MoCA (T-MoCA; range 0–22; <17 impairment) and Creyos, a computerized cognitive battery. Key variables associated with completion were assessed using logistic regressions. Mixed methods brief structured interviews and exit survey were performed to explore barriers to completing computer testing. Results: Of 791 potentially eligible patients (mean age 70 ± 14 years), there was low feasibility of remote cognitive testing, with only 401 (51%) completing the T-MoCA, and 242 (31%) completing Creyos. Our regression models show that age (ORT-MoCA: 0.95 (95% Confidence Interval (CI): 0.94–0.97); ORCreyos: 0.95 (95% CI: 0.94–0.96)), functional impairment (mRS 2–5; ORT-MoCA: 0.55 (95% CI: 0.37–0.81); ORCreyos: 0.66 (95% CI: 0.44–0.98)), quality of life (EQ-VAS; ORT-MoCA: 1.02 (95% CI: 1.01–1.03); ORCreyos: OR:1.02 (95% CI: 1.01–1.03)) and length of hospital stay (ORT-MoCA: 0.98 (95% CI: 0.96–0.99); ORCreyos: 0.97 (95% CI: 0.94–0.99)) predicted both telephone and computer cognitive test completion; computer literacy predicted computer test completion (ORCreyos: 1.12 (95% CI: 1.04–1.21)). In interviews, a preference for accessibility of computerized testing was reported. Discussion: Remote cognitive testing has limited feasibility as a secondary outcome in large acute stroke trials. Patients who are older, with worse quality of life, or severe functional impairment post-stroke are less likely to complete remote cognitive outcomes. Conclusion: Innovative approaches to post-stroke cognitive outcomes in acute stroke trials are needed. Data Access: Data available upon request.


  • Open Access

    Cognitive Assessments in Randomized Controlled Trials of Acute or Secondary Prevention Stroke Treatments 2011 to 2024: A Scoping Review

    by Sajeevan Sujanthan, Jesse Buchman, Aaron Herlick, Damyen Henderson‐Lee Wah, William Betzner, Alisia Southwell, Theresa Aves, Pugaliya Puveendrakumaran, Idris Fatakdawala, Vanessa Norouzi, et al.

    Background: Cognitive impairment after stroke is common and associated with poorer outcomes. However, cognition is rarely assessed in acute or secondary prevention randomized controlled trials (RCTs), and those that do have not been systematically synthesized. This review examines how often cognitive end points are used, specific assessments applied, domains tested, and rates of missing cognitive data. Methods: We performed a search on EMBASE, PsycINFO, MEDLINE and Cumulative Index to Nursing and Allied Health for RCTs involving adult (≥18 years) participants with stroke, published from 2011 to 2024. Abstracts and full‐text publications were screened for stroke RCTs with cognitive end points. These were categorized into acute, secondary prevention, and rehabilitation trials. Descriptive statistics summarized the frequency of cognitive end points, domains, and missing data rates in acute and prevention trials. Results: Of 12 822 screened studies, 980 met criteria for full‐text screening and 406 were stroke RCTs with a cognitive end point. Among these, 43 were acute and secondary prevention RCTs eligible for data extraction. The Mini‐Mental State Examination (22/43 studies, 52%) and Montreal Cognitive Assessment (18/43 studies, 42%) were used in the most RCTs. There were 66 distinct cognitive tasks used, with greatest diversity in memory tasks (19), executive tasks (11) and global screens (11). Mean missing data were 22.2% (SD: 10.4%, range 0%–62%). Conclusions: Cognitive tasks are infrequent outcomes in stroke RCTs. When used, the tasks and domains assessed vary widely and are heavily affected by missing data. More pragmatic approaches to measuring meaningful cognitive change in all clinical trial participants are needed.


  • Open Access

    DOC screen completion time reflects executive function, speed of processing and fluency in an observational cohort study

    by Alisia Southwell, Sajeevan Sujanthan, Tera Armel, Elaine Xing, Arunima Kapoor, Xiao Yu Eileen Liu, Krista L. Lanctot, Nathan Herrmann, Brian J. Murray, Kevin E. Thorpe, et al.

    Background The DOC screen was developed to identify Depression, Obstructive sleep apnea, and Cognitive impairment (“DOC” comorbidities) after stroke. Each component has its own score, but additional information may be gained from the time to complete the screen. Cognitive screening completion time is rarely used as an outcome measure. We assessed the added value of using DOC screen completion time as a predictor of impairment on detailed cognitive assessments. Methods Consecutive English-speaking new referrals to the stroke prevention clinic were consented to participate in detailed neuropsychological testing (n=437). DOC screen scores and times were compared to cognitive test scores using multiple linear regression and receiver operating characteristic (ROC) analysis. All linear regression analyses controlled for age, sex, years of education, and functional outcome as assessed by the modified Rankin score. Results Average completion time for the DOC screen was 3.8 ± 1.3 minutes. After accounting for age, sex and cognitive screen score, completion time was a significant independent predictor, of speed of processing (p = .002, 95% CI: -0.016 to -0.004), verbal fluency (p < .001, CI: -0.012 to -0.006) and executive (p = .004, CI: -0.006 to -0.001), but not memory, function. Completion time above 5.5 minutes (332.5 seconds) was associated with a high likelihood of impairment on gold standard executive (likelihood ratios 3.9-5.2) and speed of processing (likelihood ratio = 5.2) tasks. Conclusions DOC screen completion time is easy to collect in routine care and is independently associated with speed of processing, language and executive dysfunctions after stroke. People who take more than 5.5 minutes to complete the DOC screen are likely to have deficits in executive functioning and speed of processing. These domains can be challenging to screen for in stroke survivors, and this measure provides a simple, clinically feasible method to screen for these under-appreciated concerns. Clinical Trials Registration Identifier: NCT02363114 Clinical Trials URL: https://clinicaltrials.gov/ct2/show/NCT02363114

  • Open Access

    Parallel ventral hippocampus-lateral septum pathways differentially regulate approach-avoidance conflict

    by Dylan C. M. Yeates, Dallas Leavitt, Sajeevan Sujanthan, Nisma Khan, Denada Alushaj, Andy C. H. Lee, Rutsuko Ito

    The ability to resolve an approach-avoidance conflict is critical to adaptive behavior. The ventral CA3 (vCA3) and CA1 (vCA1) subfields of the ventral hippocampus (vHPC) have been shown to facilitate avoidance and approach behavior, respectively, in the face of motivational conflict, but the neural circuits by which this subfield-specific regulation is implemented is unknown. We demonstrate that two distinct pathways from these subfields to lateral septum (LS) contribute to this divergent control. In Long-Evans rats, chemogenetic inhibition of the vCA3- LS caudodorsal (cd) pathway potentiated approach towards a learned conflict-eliciting stimulus, while inhibition of the vCA1-LS rostroventral (rv) pathway potentiated approach non-specifically. Additionally, vCA3-LScd inhibited animals were less hesitant to explore food during environmental uncertainty, while the vCA1- LSrv inhibited animals took longer to initiate food exploration. These findings suggest that the vHPC influences multiple behavioral systems via differential projections to the LS, which in turn send inhibitory projections to motivational centres of the brain.